Skip to content
  1. Home
  2. Peptide bioregulators
  3. Prostamax

Peptide bioregulators

Prostamax

Organ-targeted peptide bioregulator designed to support prostate tissue structure and urogenital function.

Approved in Russia Peptide bioregulators Sexual health

Reviewed 2026-09-12
Full name
Prostamax (also known as Prostatilen; prostate-derived peptide bioregulator)
Also known as
Prostatilen
Regulatory status
Approved in Russia

Origin

Derived from bovine prostate tissue extracts by Khavinson's group and collaborators. Registered in Russia as injectable (cytamin/prostatamin) and oral formulations, in Russian urology and gerontology practice since the 1980s-90s under the clinical name Prostatilen.

Mechanism

Proposed to regulate prostate cell differentiation and regeneration and support structural integrity of prostate tissue, with theorized immunoprotective effects.

Research summary

Evidence

Formal human clinical trials for Prostamax are absent from PubMed. A related study on vesugen showed tissue-specific stimulation in human prostate fibroblasts, suggesting a shared mechanism; a 1997 study of a related prostate peptide preparation showed protective effects in a rat decompression model. Evidence is largely Russian-language and unreplicated in the West.

Evidence tier: Approved in Russia — see the methodology note for how this is assessed.

Citations

Reported benefits

  • support for prostate tissue structure (preclinical)
  • claimed enhancement of prostate function
  • possible support for urinary/sexual health

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous/intramuscular injection or oral tabletCommunity dosing: 10-20 mg subcutaneously or intramuscularly; oral forms 10-30 mg daily; unvalidated in humans.

Side effects

  • minimal reported; long-term monitoring data absent

Safety notes

Safety: No serious adverse events documented. Effects on hormone-sensitive prostate tissue aren't well characterized. Anyone with prostate cancer or significant prostate disease should avoid use without medical evaluation.
Community & reddit notes (anecdotal — not clinical evidence)

Discussed in men's health and biohacker communities for prostate support and urinary flow. Anecdotal only; human research validation is absent.